Humasis Co. Ltd
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface protei… Read more
Humasis Co. Ltd (205470) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.036x
Based on the latest financial reports, Humasis Co. Ltd (205470) has a cash flow conversion efficiency ratio of 0.036x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩8.98 Billion) by net assets (₩248.94 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Humasis Co. Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Humasis Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Humasis Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Humasis Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JTC Inc
KQ:950170
|
0.059x |
|
CrystalGenomics Inc
KQ:083790
|
-0.129x |
|
AstroNova Inc
NASDAQ:ALOT
|
0.044x |
|
China Fineblanking Technology Co Ltd
TWO:1586
|
0.013x |
|
NEBAG NA SF 0,02
F:NWR
|
N/A |
|
Precise Corporation Public Company Limited
BK:PCC
|
0.076x |
|
Titanium Transportation Group Inc.
TO:TTNM
|
0.119x |
|
Inhibikase Therapeutics Inc
NASDAQ:IKT
|
-0.145x |
Annual Cash Flow Conversion Efficiency for Humasis Co. Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Humasis Co. Ltd from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩229.26 Billion | ₩30.37 Billion | 0.132x | +168.60% |
| 2023-12-31 | ₩287.33 Billion | ₩-55.48 Billion | -0.193x | -133.05% |
| 2022-12-31 | ₩346.73 Billion | ₩202.60 Billion | 0.584x | -42.43% |
| 2021-12-31 | ₩202.01 Billion | ₩205.02 Billion | 1.015x | +246.69% |
| 2020-12-31 | ₩48.84 Billion | ₩14.30 Billion | 0.293x | +472.45% |
| 2019-12-31 | ₩15.24 Billion | ₩779.58 Million | 0.051x | +210.38% |
| 2018-12-31 | ₩16.13 Billion | ₩-747.08 Million | -0.046x | +75.66% |
| 2017-12-31 | ₩15.60 Billion | ₩-2.97 Billion | -0.190x | -1468.41% |
| 2016-12-31 | ₩10.86 Billion | ₩151.11 Million | 0.014x | -- |